Member Profile

PELL specializes in developing and promoting “immune cell therapy” and “stem cell regenerative medicine therapy” technologies that are in sync with Europe and the United States. It focuses on the new drug development and clinical trials of gene modified cells “Chimeric Antigen Receptor T-cell, CAR-T”. The advantages are self-development platform for CAR design, short manufacturing period (7 days), and high Tscm percentage of CAR-T product. In addition, PELL have some cell therapy products that have been approved via Regulations of Special Medical Techniques, including Cytokine-induced killer cells (CIK), Dendritic cell-Cytokine induced killer cell (DC-CIK), and Adipose-derived stem cell (ADSC).

PELL Taipei headquarters and Kaohsiung branch already built a cell processing unit (CPU) respectively that compliant with Good Tissue Practice (GTP) regulation, and both CPU facility have been approved by TFDA. The cell products from PELL are carefully manufactured at clean rooms of these authority-approved sites, and the product quality is controlled strictly. Immune cell culture technology and stem cell culture technology must be able to control technologies including specific cell isolation/purification, activation, amplification, and specific differentiation et al. With rich experience of manufacturing and quality control for therapy products, PELL can help our partners improve the goal of personalized precision cancer treatment.

For detail information, please visit website: https://www.pellbmt.com/